EP2170061A1 - Substituted pyrrolidine compounds with central nervous system activity - Google Patents
Substituted pyrrolidine compounds with central nervous system activityInfo
- Publication number
- EP2170061A1 EP2170061A1 EP08771735A EP08771735A EP2170061A1 EP 2170061 A1 EP2170061 A1 EP 2170061A1 EP 08771735 A EP08771735 A EP 08771735A EP 08771735 A EP08771735 A EP 08771735A EP 2170061 A1 EP2170061 A1 EP 2170061A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- enantiomer
- composition
- compounds
- pulse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
Definitions
- This invention relates to substituted pyrrolidine compounds having central nervous system activity.
- Central nervous system (CNS) disorders are economically and socially devastating.
- CNS Central nervous system
- schizophrenia is one of the leading causes of disability worldwide with a lifetime prevalence of 0.6 to 1.3% of the population characterized by high morbidity and mortality. Less than 15% of people with this disability are competitively employed, while about 20% live independently.
- Schizophrenia is generally characterized by positive symptoms (such as delusions, hallucinations, and disorganized behavior), negative symptoms (such as anergia), affective symptoms (such as dysphoria, hopelessness, anxiety, hostility, aggression) and/or cognitive deficits.
- Typical treatments for such disorders include drugs that affect the monoamine receptor systems.
- drugs that affect the monoamine receptor systems For example, the primary effect of first generation antipsychotics is dopamine (D2 receptor) blockade. While these are effective in treating the positive symptoms of schizophrenia, they exert only modest effects on negative symptoms and cognitive deficits.
- D2 receptor dopamine
- the present invention provides compositions comprising substituted pyrrolidines and methods of using same for central nervous system disorders.
- the compounds of the present invention have the general structure of 1.
- the Z group is a 2-naphthyl group and the compound has the general structure of 2.
- the Z group is a disubstituted phenyl group such as a 3,4-disubstituted phenyl group.
- stereochemical isomers of the substituted pyrrolidines are structures 6-9.
- the compound has the structure of DC- 16 and its enantiomer.
- the compound has the structure of DC 17 and its enantiomer.
- the compound has the structure of 12-14 and enantiomers of these compounds.
- the compounds of the present invention can be used to treat or alleviate the symptoms/causes of central nervous system disorders.
- Figure 1 Graphical representation of movement data from ckr mouse screening test.
- Figure 2 Graphical representation of startle amplitude data from ckr mouse screening test.
- the present invention provides compositions of substituted pyrrolidine compounds that can function as monoamine transporter inhibitors, and act as selective serotonin transporter (SERT) inhibitors. These compounds can be used for alleviating the symptoms of CNS disorders.
- SERT serotonin transporter
- the compounds of the present invention have the following general structure (structure (I)): wherein
- the substituents on the pyrrolidine ring, Ri and R 2 can be H, hydroxy or alkoxy (ORx), carboxylic acid or carboxylate (C(O)ORx), or amido (C(O)N(Rx)Rx (the amido group can be unsubstituted (both Rx groups are H; C(O)NH 2 ) or substituted (one or both Rx groups are not H; C(O)NHRx or C(O)N(Rx)Rx)).
- Rx can be a hydrogen, alkyl (such as -CH 3 ) or alkenyl group (a group with a carbon-carbon double bond) comprising 8 carbons or less, aryl group (a cyclic aromatic hydrocarbon that can be substituted or unsubstituted), or amino group (including substituted or unsubstituted amines).
- Ri and R 2 substituents if Ri is ORx, C(O)ORx or C(O)N(Rx)Rx, then R 2 is H and the compound is a 2,4-substituted pyrrolidine.
- R 2 is ORx, C(O)ORx or C(O)N(Rx)Rx, then Rl is H and the compound is a 2,3-substituted pyrrolidine.
- R 3 can be C(O)ORy or CH 2 ORy, and Ry is a hydrogen, alkyl or alkenyl group comprising 8 carbons or less, aryl group, or amino group.
- R 4 can be an alkyl, aryl, alkenyl, alkoxy, halo (fluoro, chloro, bromo, or iodo), nitro (- NO 2 ), cyano (-CN), keto (-C(O)R, where R is an alkyl chain comprising 8 carbons or less), amino, or carboxylate group.
- R 5 can be an alkyl, aryl, alkenyl, alkoxy, halo, nitro, cyano, keto, amino, carboxylate group.
- R 6 can be alkyl, aryl, alkenyl, alkoxy, halo, nitro, cyano, keto, amino, carboxylate.
- R 7 can be alkyl, aryl, alkenyl, alkoxy, halo, nitro, cyano, keto, amino, carboxylate.
- the Z group of the compound is a 2-naphthyl group and the compound has general structure (2) or its enantiomer (3).
- the Z group of the compound is a 3,4-disubstituted phenyl group and the compound has the general structure of 4 or its enantiomer 5.
- the Z group of the compound is a disubstituted phenyl group (such as 2,3-, or 2,4-disubstituted).
- the present invention includes all stereoisomers (including enantiomers and diastereomers) that can be formed from the various substitutions and orientations of structure 1.
- the compound has diastereomeric structure 6 or its enantiomer (structure 7), which can be prepared by the general synthetic methodology described in Example 1.
- the compound has diastereomeric structure 8 or its enantiomer (structure 9), which can be prepared by the general synthetic methodology described in Example 1.
- Examples of compounds of the present invention include, but are not limited to, the following structures and their enantiomers:
- compositions can comprise enantiomers or racemic mixtures of these compounds as well.
- the compounds above can have other stereochemical configurations, where one or two of the stereocenters have been inverted. This includes the threo- diastereomeric structure in which the stereocenter in the side chain group has been inverted. It also includes the diastereomeric series where the stereocenter in the ring (Ri and/or R 2 ) have been inverted.
- the compositions can comprise a diastereomeric mixture of these stereoisomers as well as their enantiomers.
- These compounds may be administered orally, parenterally, intramuscularly, intravenously, mucosally or by other route.
- Other ingredients may be added to the compounds as part of the pharmaceutical composition depending on the dosage form, particular needs of the patient, and method of manufacture, among other things. Examples include, but are not limited to, binders, lubricants, fillers, flavorings, preservatives, colorings, diluents, etc.
- binders binders, lubricants, fillers, flavorings, preservatives, colorings, diluents, etc.
- the selection of particular substances and their compatibilities with the compositions of the present invention can be readily ascertained by those of ordinary skill in the art. Details are also provided in U.S. Patent No. 5,763,455, which is incorporated herein by reference.
- the route of administration is oral.
- the dosage regimen of these compounds is well within the purview of those skilled in the art.
- the dose levels may be from 4 micrograms per kilogram of body weight up to 50 milligrams/Kg of body weight.
- the dose may be from 20 micrograms/Kg up to 15 mg/Kg.
- the chakragati (ckr) mouse model was used to demonstrate the in vivo efficacy of the presently claimed compositions in reducing symptoms of neuropsychiatric disorders. (See Example 4) The efficacy of the compositions is demonstrated using a mouse model described in U.S. Patent No. 5,723,719, the description of which is incorporated herein by reference.
- the ckr mouse model is a transgenic mouse which exhibits motor activity and social behaviors characteristic of schizophrenia.
- the ckr mouse was serendipitously created as a result of a transgenic insertional mutation.
- the apparent loss-of function of endogenous genes and associated genetic rearrangements resulted in a transgenic mouse that in the homozygous condition, exhibited an abnormal circling phenotype.
- the increased motor activity in these mice is similar to that observed in wild-type mice treated with NMDA (N-methyl-D-aspartic acid) receptor antagonists, which produce behaviors resembling the positive symptoms of schizophrenia.
- the ckr mouse also appears to show reduced social interactions resembling the social withdrawal that is part of the constellation of negative symptoms of schizophrenia.
- the mouse also presents lateral ventricular enlargement, which may mirror neuropathological observations in schizophrenia. Atypical antipsychotics clozapine and olanzapine have been shown to reduce the characteristic circling behavior of the mice. These data collectively suggest that the ckr mouse may model certain aspects of the pathology of schizophrenia.
- the model has been further validated by testing risperidone, haloperidol and pimozide in the ckr mouse.
- the behavioral output was assayed by measuring the rate of hyperactivity and circling after administration.
- the results demonstrated a dose-dependent attenuation of hyperactivity in ckr mice for risperidone, clozapine, haloperidol and pimozide in concentrations relevant to human clinical use.
- the ckr mouse model is considered to be valid for evaluation of compounds for use in reducing the symptoms of neuropsychiatric disorders in mammals, including humans.
- PPI Pre-pulse inhibition
- Example 4 To obtain the ckr mouse model data presented in Example 4, a variety of related compounds, including compounds of the present invention, were used to investigate a standard measure of sensorimotor gating of the startle reflex. Sensorimotor gating of the startle reflex was assessed via measures of PPI, which is the reduction in startle magnitude when the startling stimulus is preceded immediately by a weak pre-pulse. This measurement is valuable because the relative loss of PPI has been established in inherited neurodevelopmental disorders, such as schizophrenia in humans, as well as in rats after treatment with certain classes of drugs, including serotonin (5-HT) agonists.
- PPI serotonin
- This example describes the synthesis of compounds of the present invention.
- a substituted pyrrolidine ((R)-methyl 2-((2S,4R)-4-hydroxypyrrolidin-2-yl)-2- (naphthalen-2-yl)acetate hydrochloride) (HDMP-80) was synthesized using a C-H activation step.
- This reaction preferentially forms the eyrthro product with high diastereo- and enantioselectivity.
- the reaction is catalyzed by a chiral catalyst, Rh 2 (S-DOSP) 4 , that controls which position of the pyrrolidine ring is functionalized (C2 or C5).
- synthesis of the substituted pyrrolidines of the present invention was achieved using the reaction scheme shown above.
- a variety of methyl aryldiazoacetates can be reacted with 3 -substituted, iV-Boc-protected pyrrolidines (in the case of hydroxy-substituted pyrrolidines) to generate 2,4-disubstituted and 2,3-disubstituted pyrrolidine derivatives.
- the diastereoselectivity of the products is, generally, greater than 95 percent when starting with enantiomerically pure or substantially pure substituted pyrrolidines.
- the neutral base was converted to the hydrochloride salt by dissolving the base in dry ether followed by addition of ethereal HCl and isolation of the salt by filtration.
- the enantiomer was prepared by starting with the enantiomers of the catalyst and the substrate described above. Synthesis of (RVmethyl 2-((2S ⁇ RV4-hvdroxypyrrolidin-2-v0-2-(naphthalen-2-v0acetate (HDMP 80).
- the aqueous phase was then back extracted ethyl acetate (3 x 50 mL) and the organic phases were washed with brine (25 mL), dried with Na 2 SO 4 , and filtered.
- the extraction was reduced and purified by chromatography to afford the titled compound as a clear oil: (672 mg, 64% yield).
- the neutral base was converted to the hydrochloride salt by dissolving the base in dry ether followed by addition of ethereal HCl and isolation of the salt by filtration.
- the enantiomer was prepared by starting with the enantiomers of the catalyst and the substrate described above. Synthesis of (3R,5S)-5-((R)-2-(hvdroxy-l-(naphthalen-2-yl)ethyl)pyrrolidin-3-ol hydrochloride (HDMP 86).
- Binding of substituted pyrrolidine compounds at biogenic amine transporters was determined using striatum and frontal cortex dissected from frozen Sprague-Dawley rat brains (Pel-Freez, Rogers, AR). Affinities of the compounds at dopamine (DA) transport sites were determined by displacement of [ 125 I] 3 beta-(4-iodophenyl)tropan-2 beta-carboxylic acid methyl ester (RTI-55) binding in membranes from rat striatum, using 0.5 mg (original wet weight) of membranes and 10 pM [125i]RTi-55.
- Non-specific binding was determined in the presence of 1 ⁇ M 2 ⁇ -propanoyl-3 ⁇ -(2-naphthyl) tropane (WF-23). Affinities of the compounds at 5-HT transport sites were determined by displacement of [3H]paroxetine binding in membranes from rat frontal cortex, using 50 mg (original wet weight) of membranes and 0.4 nM [ 3 H]paroxetine. Non-specific binding was determined in the presence of 10 ⁇ M fluoxetine. Binding of the compounds at norepinephrine (NE) transport sites was determined by displacement of [3H]nisoxetine binding in membranes from rat forebrain, using 0.7 nM [3H]nisoxetine. Non- specific binding was determined in the presence of 1 ⁇ M desipramine.
- NE norepinephrine
- Potencies in Figures 3 and 4 were calculated from displacement curves using 7-10 concentrations of unlabeled compounds, as analyzed by non- linear curve fitting. Because the binding of substituted pyrrolidines at dopamine transporters is generally regarded as multiphasic, potencies in inhibiting [ 125 I]RTI-55 binding are reported as IC50 values. For [ 3 H]paroxetine and [ 3 H]nisoxetine binding assays, Ki values were calculated using the Cheng- Prusoff equation. All data are mean values ⁇ SEM (standard error measurement) of at least three separate experiments, each of which was conducted in triplicate. Biological activity.
- DA dopamine
- 5-HT serotonin
- NE norepinephrine
- the compounds of the present invention displayed biological activity, many having desirable binding affinities to dopamine and norepinephrine transporters. Compounds binding to more than one monoamine transporter have been shown to be effective as antidepressants and so, the substituted pyrrolidine derivatives of the present invention are expected to have similar activity.
- a preferred compound is HDMP-80 which shows high binding affinity for the serotonin transporter.
- mice Male and female, 3 months old were randomly assigned to receive test drugs or 0.5 % DMSO vehicle. Each drug was tested in 5 mice. Each mouse received up to 5 randomly assigned drugs in random order. Each treatment was separated by a minimum washout period of 3 days. On the day of testing, mice were brought into the behavioral test room and allowed to acclimatize for at least 1 hour. They then received intraperitoneal injections of the 0.1 mL/10 g (10 mg/kg) of the test drug solutions or vehicle.
- mice were returned to their cage and 20 minutes later they were placed in a 190 mm diameter, 300 mm deep circular recording chamber.
- Four mice were tested simultaneous in 4 separate chambers. Between each testing session the chambers were wiped down with 70% ethanol and allowed to dry for at least 10 minutes The mice were monitored with an overhead video camera for 15 min. Their behavior was videotaped and simultaneously digitized and tracked (Ethovision Version 2, Noldus). The total distance moved, the velocity of movement, and the time spent moving were calculated.
- the chamber consisted of a clear plexi-glass cylinder resting on a platform inside a ventilated, sound-attenuating chamber.
- a high frequency loudspeaker inside the chamber produced both a continuous background noise of 65 dB as well as the various acoustic stimuli.
- mice There were 8 mice in each group. The mice were acclimatized for 60 minutes in the behavioral test room prior to measurement of PPI. They were then placed in the plexiglass cylinder and exposed to 65 dB background white -noise. After 5 minutes, the mice were exposed to a series of 5 different types of trials involving exposure to pulses of white -noise: (1) pulse- alone trials, during which a 120 dB stimulus was presented for 40 milliseconds (ms); (2) +3 dB pre-pulse trials, during which a 20 ms, 68 dB (+3 dB above 65 dB background) pre-pulse preceded the 120 dB pulse by the pre-pulse to pulse interval; (3) +6 dB pre-pulse trials, during which a 20 ms, 71 dB (+6 dB above 65 dB background) pre-pulse preceded the 120 dB pulse by the pre-pulse to pulse interval; (4) +12 dB pre-pul
- the pre-pulse to pulse interval was set at 100 ms.
- a characteristic of pre-pulse inhibition is that the phenomenon disappears at very short pre-pulse to pulse intervals.
- the protocol was subsequently repeated with 25 ms, 100 ms, and 175 ms pre-pulse to pulse intervals in pseudorandom order to confirm that the effect seen was a pre-pulse inhibition.
- a total of 52 trials were conducted in pseudorandom order: 20 pulse alone trials, and 8 each of the other four trials. These were preceded by 4 pulse alone trials, which were discarded.
- the average inter-trial interval was 15 seconds (9-21 second range).
- the startle response was recorded as the average movement detected over 65 ms following the pulse. Cases were the startle response amplitude on the pre-pulse trial exceeded 90 % of the average startle response amplitude on the pulse alone trials were excluded. The startle amplitude was measured as the average startle response for the pulse-alone trials. Pre- pulse inhibition was calculated as percentage PPI, namely as (A - B) / A x 100, where A was the average startle response amplitude on pulse-alone trials and B was the average startle response amplitude on pre -pulse trials. Use of this measure, in preference to absolute difference scores, minimizes the possible effects of individual differences in startle amplitude on PPI. Results of ckr mouse screening tests.
- DC 15 proved lethal at 10 mg/kg in 3 mice. Treatment with DC 15 was discontinued.
- DCl 1 and DC12 both increased PPI over the vehicle control (p ⁇ 0.01 and p ⁇ 0.05, respectively), while DC 18 produced a similar but insignificant trend (Figure 2 d).
- DCl 1 consistently produced significant recovery of PPI, while only DC 18 produced a similar trend across all pre-pulse intensities. Discussion of results.
- DCOl, DC08, DC12 and DC19 increased motor activity but had little consistent effect on PPI. Increases, in motor activity are likely to relate to increases in dopaminergic function.
- the effect on circling in the ckr mouse suggests that these drugs are bioavailable in the central nervous system after systemic administration. That these drugs did not alter PPI or worsen the deficits in PPI in the ckr mouse suggests that they are unlikely to produce severe sensorimotor processing deficits.
- the profile of these drugs suggests that they are centrally active after systemic administration and increase dopaminergic function.
- An ANOVA analysis of the ckr screening data shown in Figures 1 and 2 indicates that DC 16 has biological activity as an agent to treat CNS disorders.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94574607P | 2007-06-22 | 2007-06-22 | |
PCT/US2008/067884 WO2009002923A1 (en) | 2007-06-22 | 2008-06-23 | Substituted pyrrolidine compounds with central nervous system activity |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2170061A1 true EP2170061A1 (en) | 2010-04-07 |
EP2170061A4 EP2170061A4 (en) | 2012-01-11 |
Family
ID=40186006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08771735A Withdrawn EP2170061A4 (en) | 2007-06-22 | 2008-06-23 | Substituted pyrrolidine compounds with central nervous system activity |
Country Status (6)
Country | Link |
---|---|
US (1) | US8329741B2 (en) |
EP (1) | EP2170061A4 (en) |
JP (1) | JP2010530900A (en) |
CN (1) | CN101677546A (en) |
BR (1) | BRPI0811698A2 (en) |
WO (1) | WO2009002923A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2992645B1 (en) * | 2012-07-02 | 2014-08-01 | Univ Claude Bernard Lyon | NEW PYRROLIDINE DERIVATIVES |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2081433A1 (en) * | 1970-01-15 | 1971-12-03 | Ciba Geigy Ag |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6410746B1 (en) * | 1999-04-27 | 2002-06-25 | Research Foundation Of State University Of New York, The | Metal cataltsts and methods for making and using same |
US20060241144A1 (en) * | 2005-04-20 | 2006-10-26 | Albert Cha | Method for treating apathy syndrome |
-
2008
- 2008-06-23 US US12/144,232 patent/US8329741B2/en not_active Expired - Fee Related
- 2008-06-23 EP EP08771735A patent/EP2170061A4/en not_active Withdrawn
- 2008-06-23 WO PCT/US2008/067884 patent/WO2009002923A1/en active Application Filing
- 2008-06-23 BR BRPI0811698-9A2A patent/BRPI0811698A2/en not_active IP Right Cessation
- 2008-06-23 CN CN200880021352A patent/CN101677546A/en active Pending
- 2008-06-23 JP JP2010513483A patent/JP2010530900A/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2081433A1 (en) * | 1970-01-15 | 1971-12-03 | Ciba Geigy Ag |
Non-Patent Citations (7)
Also Published As
Publication number | Publication date |
---|---|
EP2170061A4 (en) | 2012-01-11 |
CN101677546A (en) | 2010-03-24 |
US20090048329A1 (en) | 2009-02-19 |
WO2009002923A1 (en) | 2008-12-31 |
JP2010530900A (en) | 2010-09-16 |
US8329741B2 (en) | 2012-12-11 |
BRPI0811698A2 (en) | 2014-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101465178B1 (en) | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | |
JP6876675B2 (en) | Muscarine agonist | |
EP0673928B1 (en) | Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selective human NK3-receptor antagonists | |
RU2351588C2 (en) | N-phenyl(piperidine-2-yl)methyl-benzamide derivatives, and their application in therapy | |
JP6843114B2 (en) | Muscarine agonist | |
IL110512A (en) | Diarylmethyl piperazine derivatives their preparation and pharmaceutical compositions containing them | |
FR2838739A1 (en) | New N-(piperidinyl-benzyl)-trifluoromethyl-benzamides, are glyt1 and/or glyt2 glycine transporter inhibitors, useful e.g. for treating schizophrenia, depression, muscle spasms, pain or epilepsy | |
EA009942B1 (en) | Azabicyclo derivatives as muscarinic receptor antagonists | |
JP2006522788A (en) | Azabicyclo derivatives as muscarinic receptor antagonists | |
US20120101129A1 (en) | Methylphenidate Derivatives and Uses of Them | |
US8329741B2 (en) | Substituted pyrrolidine compounds with central nervous system activity | |
CA2888024C (en) | Fluorine substituted cyclic amine compounds and preparation methods, pharmaceutical compositions, and uses thereof | |
EP2473489A1 (en) | 2-(1,2-benzisoxazol-3-yl)benzylamine derivatives | |
JPH02275851A (en) | Hydrocarbon-substituted pyrrolidinone | |
WO2015046405A1 (en) | Analgesic | |
AU751592B2 (en) | Ureidopiperidine derivatives as selective human NK3 receptor antagonists | |
US7851487B2 (en) | Use of tetrahydropyridines in the treatment of central nervous system disorders | |
EP3964497A1 (en) | Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain | |
WO1995025100A1 (en) | Use of 4-amino-5-chloro-2-methoxybenzoic esters as 5-ht4 agonists | |
US7851488B2 (en) | Tetrahydropyridines with central nervous system activity | |
FR2717174A1 (en) | Use of 4-amino-5-chloro-2-methoxy-benzoic acid piperidino-ethyl ester(s) | |
FR2755133A1 (en) | NEW DERIVATIVES OF VARIOUSLY SUBSTITUTED CYCLIC AMIDS SELECTIVE ANTAGONISTS OF THE HUMAN NK3 RECEIVER, PROCESS FOR THEIR OBTAINING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
ZA200500952B (en) | 3,6 Disubstituted azabicyclo (3.1.0) hexane derivatives useful as muscarinic receptor antagonists. | |
KR20060014373A (en) | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100115 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DAVIES, HUW, M.L. |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/24 20060101ALI20111130BHEP Ipc: A61P 25/18 20060101ALI20111130BHEP Ipc: A61K 31/40 20060101ALI20111130BHEP Ipc: A01N 43/36 20060101AFI20111130BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20111208 |
|
17Q | First examination report despatched |
Effective date: 20111216 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20120627 |